The pathogenesis of rheumatoid arthritis: A guide to therapy

American Journal of the Medical Sciences

Volumn 323, Issue 4, 2002, Pages 171-180

  Jenkins, John K ^a   Hardy, Kenneth J ^a,b   McMurray, Robert W ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Rheumatology Section   (United States)

Author keywords

Cytokines; Macrophages; Pathogenesis; Rheumatoid arthritis; T cells

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 7; MATRIX METALLOPROTEINASE; OSTEOPROTEGERIN; PROSTAGLANDIN; TUMOR NECROSIS FACTOR;

ARTHROPATHY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG TARGETING; FIBROBLAST; HUMAN; IMMUNOPATHOLOGY; LYMPHOCYTE; MEDIATOR RELEASE; MEDICAL RESEARCH; MONOCYTE; NONHUMAN; PATHOGENESIS; PHYSICAL DISABILITY; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 0036083566     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200204000-00002     Document Type: Article

References (72)

1. Etiology and pathogenesis of rheumatoid arthritis
2. Persistence of B19 parvovirus in synovial membranes with rheumatoid arthritis
3. Rheumatoid arthritis - Heresies and speculations
4. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes
5. Role of cytokines in rheumatoid arthritis
6. Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis
7. How important are T cells in chronic rheumatoid synovitis?
8. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?
9. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis
10. HLA genes associated with rheumatoid arthritis: Identification of susceptibility alleles using specific oligonucleotide probes
11. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis
12. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation
13. Tumor necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis
14. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis
15. Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis
16. Mortality in the rheumatic diseases
17. Long-term outcomes in rheumatoid arthritis
18. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
19. Role of pro-inflammatory cytokines in rheumatoid arthritis
20. The role of cytokines in the pathogenesis of rheumatoid arthritis
21. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis
22. Anchorage-independent growth of synoviocytes from arthritis and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids
23. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovitis fibroblast
24. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium
25. Regulation of synoviocyte proliferation, apoptosis, and invasion by the tumor suppressor gene
26. Monoclonal expansion of synoviocytes in rheumatoid arthritis
27. Telomerase activity in rheumatoid synovium correlates with the mononuclear cell infiltration level and disease aggressiveness of rheumatoid arthritis
28. Synovial fibroblast-like cells strongly express jun-B and c-fos proto-oncogenes in rheumatoid- and osteoarthritis
29. Rheumatoid arthritis and apoptosis
30. The role of the DR4 shared epitope in selection and commitment of autoreactive T cells in rheumatoid arthritis
31. Pathogenesis of rheumatoid arthritis: The role of T cells and other beasts
32. Do lymphocytes protect the rheumatoid joint?
33. Reduction of synovial inflammation after anti CD-4 monoclonal antibody treatment in early rheumatoid arthritis
34. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor alpha, but not interleukin 10: Possible relevance to pathophysiology of rheumatoid arthritis
35. Gold treatment of rheumatoid arthritis decreases synovial expression of endothelial leukocyte adhesion receptor ELAM-1
36. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
37. The simultaneous occurrence of rheumatoid arthritis and agammaglobulinemia
38. The immunologic homunculus in rheumatoid arthritis
39. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial
40. An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis
41. Role of adhesion molecules in the pathogenesis of rheumatoid arthritis
42. Cell adhesion molecules in rheumatoid arthritis
43. Cell adhesion molecules in rheumatoid arthritis
44. Adhesion molecules in autoimmune disease
45. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin, and P-selectin) in rheumatoid arthritis
46. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissues of rheumatoid arthritis patients
47. Drugs, inflammation, and cell adhesion receptors
48. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
49. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1
50. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
51. The role of tumor necrosis factor in health and disease
52. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
53. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee joints of patients with rheumatoid arthritis
54. Cachectin/tumor necrosis factor α stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
55. Prostaglandin E2, Interleukin 1α, and tumor necrosis factor α increase human osteoclast formation and bone resorption in vitro
56. Periarticular osteopenia in adjuvant induced arthritis: Role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells
57. 2, interleukin 1α, and tumor necrosis factor-a increase human osteoclast formation and bone resorption in vitro
58. An interleukin 1 like factor stimulates bone resorption in vitro
59. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data
60. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid rathritis
61. Arguments for interleukin 1 as a target in chronic arthritis
62. Potential biologic agents for treating rheumatoid arthritis
63. Inhibition of tumor necrosis factor α-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways
64. Effects of IL-10 on interleukin 1 receptor antagonist and interluekin-1b production in human monocytes and neutrophils
65. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis
66. Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B
67. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: Application to catabolism in situ and in vivo
68. Nitric oxide synthase and cyclooxygenases: Distribution, regulation, and intervention in arthritis
69. The role of nitric oxide in inflammation and immunity
70. Inducible nitric oxide synthase in inflammation
71. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation
72. Clinical management of rheumatoid arthritis